Ubrogepant has 17 known drug interactions based on U.S. FDA drug labeling data. Of these, 3 are contraindicated combinations that should be avoided entirely. 4 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Clarithromycin, Itraconazole, Ketoconazole. Patients taking Ubrogepant should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 17
- Contraindicated
- 3
- Major
- 4
- Moderate
- 10
Contraindicated (3)
- Ubrogepant + Clarithromycin— Strong CYP3A4 inhibitor. Should not be used with ubrogepant due to increased exposure risk.
- Ubrogepant + Itraconazole— Strong CYP3A4 inhibitor. Should not be used with ubrogepant due to increased exposure risk.
- Ubrogepant + Ketoconazole— Strong CYP3A4 inhibitor resulting in significant increase in ubrogepant exposure. Contraindicated for concomitant use.
Major (4)
- Ubrogepant + Barbiturates— Strong CYP3A4 inducer expected to cause loss of ubrogepant efficacy. Concomitant use should be avoided.
- Ubrogepant + Phenytoin— Strong CYP3A4 inducer expected to cause loss of ubrogepant efficacy. Concomitant use should be avoided.
- Ubrogepant + Rifampin— Strong CYP3A4 inducer resulting in significant reduction in ubrogepant exposure and loss of efficacy. Concomitant use sh…
- Ubrogepant + St. John'S Wort— Strong CYP3A4 inducer expected to cause loss of ubrogepant efficacy. Concomitant use should be avoided.
Moderate (10)
- Ubrogepant + Carvedilol— BCRP and/or P-gp inhibitor that may increase ubrogepant exposure. Dose adjustment recommended.
- Ubrogepant + Ciprofloxacin— Dose adjustment is recommended with concomitant use of UBRELVY and moderate CYP3A4 inhibitors (e.g., cyclosporine, cipro…
- Ubrogepant + Curcumin— BCRP and/or P-gp inhibitor that may increase ubrogepant exposure. Dose adjustment recommended.
- Ubrogepant + Cyclosporine— Moderate CYP3A4 inhibitor. Dose adjustment recommended with concomitant use.
- Ubrogepant + Eltrombopag— BCRP and/or P-gp inhibitor that may increase ubrogepant exposure. Dose adjustment recommended.
- Ubrogepant + Fluconazole— Dose adjustment is recommended with concomitant use of UBRELVY and moderate CYP3A4 inhibitors (e.g., cyclosporine, cipro…
- Ubrogepant + Fluvoxamine— Moderate CYP3A4 inhibitor. Dose adjustment recommended with concomitant use.
- Ubrogepant + Grapefruit Juice— Moderate CYP3A4 inhibitor. Dose adjustment recommended with concomitant use.
- Ubrogepant + Quinidine— BCRP and/or P-gp inhibitor that may increase ubrogepant exposure. Dose adjustment recommended.
- Ubrogepant + Verapamil— Moderate CYP3A4 inhibitor resulting in increased ubrogepant exposure. Dose adjustment recommended.